In the 1970s, the Johns Hopkins University School of Medicine (JHUSOM) and Harvard Medical School discovered that antisense oligonucleotides (ASON) could actually block the expression of specific genes. Since then, a new genetic engineering technology—antisense technology—has emerged. According to the principle of complementary base pairing, ASON is specifically used to bind the genes or mRNA in cells and regulate gene expression by blocking the transcription of gene or translation of mRNA. After the artificially synthesized radionuclide-labeled ASON is introduced into the body, it binds specifically to intracellular target genes or mRNAs through the principle of complementary base pairing, and then an imaging instrument is used to display the target genes or tissue that is overexpressed in genes, thereby forming a new diagnosis method—radionuclide antisense gene imaging [1, 2].